Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

The Hydrogel Endovascular Aneurysm Treatment Trial (HEAT): A Randomized Controlled Trial of the Second-Generation Hydrogel Coil
Bendok, Bernard R. , Abi-Aad, Karl R., Ward, Jennifer , Kniss, Jason F , Kwasny, Mary , Rahme, Rudy J. , Aoun, Salah G. , Tecle, Najib E. El , Zammar, Samer G. , Aoun, Rami James N. , Patra, Devi Prasad, Raymond, Jean , Woo, Henry H. , Dabus, Guilherme , Milot, Geneviève , Scott, John A. , DeNardo, Andrew , Investigators, HEAT Study, Lavine, Sean D., Bozorgchami, Hormozd, Veznedaroglu, Erol, Albuquerque, Felipe C. , Fiorella, David, Boulos, Alan S. , Cortes, Maria, Kanaan, Hilal, Jindal, Gaurav , Klucznik, Richard , Kalmes, David, Xavier, Andrew, Hussain, Muhammad , Moran, Christopher J. , Adel, Brian van , Milot, Genevieve, Hirsch, Joshua A , Carpenter, Jeffrey , Powers, Ciarán J. , Luh, George, Tummala, Ramanchandra, Evans, Avery J. , Garg, Ankur, James, Roberts, Sauvageau, Eric , Fields, Jeremy D. , Grobelny, Thomas, Hartman, J., Patra, Devi P. , Bendok, Bernard R , Ward, Jennifer D, Ahmadieh, Tarek Y. El , Ansari, Sameer A. , Fiorella, David , Dabus, Guilherme C. , Almandoz, Josser E Delgado , Dashti, Shervin R , Investigators, HEAT Study, Deshaies, Eric Michael , Fiorella, David, Tawk, Rabih G. , Romero, Charles, Kelly, Michael , Chaudry, Imran , Pandey, Aditya S , Wang, Dennis Y.Q. , Milot, Genevieve, Jabbour, Pascal , Shankar, Jai , Patsalides, Athos T , Lee, Sung , James, Robert F. , Jayaraman, Mahesh V. , Satti, Sudhakar R

Mayo Clinic

Neurosurgery | February 10, 2020 | Volume: 86 | Issue: 5 | Pages: 615-624

10.1093/neuros/nyaa006 | PMID 32078692 Get It

Abstract BACKGROUND Aneurysm recurrence after coiling has been associated with aneurysm growth, (re)hemorrhage, and a greater need for follow-up. The second-generation HydroCoil Embolic System (HES; MicroVention, Inc) consists of a platinum core with integrated hydrogel and was developed to reduce recurrence through enhancing packing density and healing within the aneurysm. OBJECTIVE To compare recurrence between the second-generation HES and bare platinum coil (BPC) in the new-generation Hydrogel Endovascular Aneurysm Treatment Trial (HEAT). METHODS HEAT is a randomized, controlled trial that enrolled subjects with ruptured or unruptured 3- to 14-mm intracranial aneurysms amenable to coiling. The primary endpoint was aneurysm recurrence using the Raymond-Roy scale. Secondary endpoints included minor and major recurrence, packing density, adverse events related to the procedure and/or device, mortality, initial complete occlusion, aneurysm retreatment, hemorrhage from target aneurysm during follow-up, aneurysm occlusion stability, and clinical outcome at final follow-up. RESULTS A total of 600 patients were randomized (HES, n = 297 and BPC, n = 303), including 28% with ruptured aneurysms. Recurrence occurred in 11 (4.4%) subjects in the HES arm and 44 (15.4%) subjects in the BPC arm ( P = .002). While the initial occlusion rate was higher with BPC, the packing density and both major and minor recurrence rates were in favor of HES. Secondary endpoints including adverse events, retreatment, hemorrhage, mortality, and clinical outcome did not differ between arms. CONCLUSION Coiling of small-to-medium aneurysms with second-generation HES resulted in less recurrence when compared to BPC, without increased harm. These data further support the use of the second-generation HES for the embolization of intracranial aneurysms. Video Abstract
Development and Pilot Testing of Decision Aid for Shared Decision Making in Barrett’s Esophagus With Low-Grade Dysplasia
Krishnamoorthi, Rajesh , Hargraves, Ian , Gopalakrishnan, Naveen, Blevins, Christopher H. , Priyan, Harshith, Johnson, Michele L., Maixner, Kristyn, Wang, Kenneth K, Katzka, David A. , Talwalkar, Jayant A., Iyer, Prasad G. , LeBlanc, Annie

Mayo Clinic

Journal of Clinical Gastroenterology | February 10, 2020 | Volume: 55 | Issue: 1 | Pages: 36-42

10.1097/mcg.0000000000001319 | PMID 32040049 Get It

Goals: To develop an encounter decision aid [Barrett’s esophagus Choice (BE-Choice)] for patients and clinicians to engage in shared decision making (SDM) for management of BE with low-grade dysplasia (BE-LGD) and assess its impact on patient-important outcomes. Background: Currently, there are 2 strategies for management of BE-LGD—endoscopic surveillance and ablation. SDM can help patients decide on their preferred management option. Study: Phase-I: Patients and clinicians were engaged in a user-centered design approach to develop BE-Choice. Phase-I included review of evidence on BE-LGD management, observation of usual care (UC), creation, field-testing, and iterative development of BE-Choice in clinical settings. Phase-II: Impact of BE-Choice on patient-important outcomes (patient knowledge, decisional conflict, and patient involvement in decision making) was assessed using a controlled before-after study design (UC vs. BE-Choice). Results: Phase-I: Initial prototype was designed with observation of 8 clinical encounters. With field-testing, 3 successive iterations were made before finalizing BE-Choice. BE-Choice was paper based and fulfilled the qualifying criteria of International patient decision aid standards. Phase II: 29 patients were enrolled, 8 to UC and 21 to BE-Choice. Compared with UC, use of BE-Choice improved patient knowledge (90.4% vs. 70.5%; P =0.03), decisional comfort (89.6 vs. 71.9; P =0.01), and patient involvement (OPTION score: 27.1 vs. 19.2; P =0.01). Conclusions: BE-Choice is a feasible and effective decision aid to promote SDM in the management of BE-LGD. On pilot testing, BE-Choice had promising impact on patient-important outcomes. A larger multicenter trial is needed to confirm our results and promote widespread use of BE-Choice.
Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial
Brandler, Justin , Burton, Duane D. , Busciglio, Irene, Arndt, Kayla, Harmsen, William S. , Camilleri, Michael , Miller, Laurence J. , Burton, Duane, Camilleri, M , Wang, Xiao‐Jing

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | February 10, 2020 | Volume: 318 | Issue: 4 | Pages: G635-G645

10.1152/ajpgi.00371.2019 | PMID 32036693 Get It

Abnormal gastric accommodation (GA) and gastric emptying contribute to pathophysiology in functional dyspepsia (FD). Secretin is a key regulator of GA in animal studies. Our aim was to study the effects of secretin on gastric motility, satiation, postprandial symptoms, and key hormones. We performed two double-blind, randomized, saline-controlled crossover trials in 10 healthy volunteers and 10 patients with FD by Rome IV criteria. We used measured GA (by validated SPECT method) after a 111In radiolabeled Ensure 300-mL meal and quantified gastric emptying for 30 min by scintigraphy. Satiation was measured by volume to fullness (VTF) and maximum tolerated volume (MTV) on an Ensure nutrient drink test and postprandial symptoms 30 min post-MTV. Fasting and postprandial GLP-1, GIP, and HPP were measured. The ages and sex distribution of healthy controls and patients with FD were similar. Compared with placebo, secretin delayed gastric emptying at 30 min in both health [−11% (−16, −4), P = 0.004]; and FD [−8% (−9, 0), P = 0.03]. Satiation (VTF and MTV), GA, and plasma levels of GLP-1, GIP, and HPP did not differ between treatment arms in health or FD. On ANCOVA analysis (adjusting for age and sex), secretin did not consistently increase postprandial symptoms in health or FD. Secretin delayed gastric emptying in both health and FD without significantly altering GA, VTF, or MTV or selected hormones. Thus, secretin receptor activation may provide a novel therapeutic mechanism for patients with FD and rapid gastric emptying. NEW & NOTEWORTHY The naturally occurring hormone secretin retards gastric emptying of solids without deleteriously affecting gastric accommodation, satiation, other upper gastrointestinal hormones, or postprandial symptoms. Given these findings, a subset of patients with rapid gastric emptying (e.g., the estimated 20% of patients with functional dyspepsia) could be candidates for treatments that stimulate a secretin receptor such as sacubitril, which inhibits neprilysin, an enzyme that degrades secretin.
Phase I study of AR-42 and decitabine in acute myeloid leukemia
Liva, Sophia G. , Coss, Christopher C. , Wang, Jiang , Blum, William , Klisovic, Rebecca B. , Bhatnagar, Bhavana , Walsh, Katherine, Geyer, Susan M. , Zhao, Qiuhong , Garzon, Ramiro , Marcucci, Guido , Phelps, Mitch A. , Walker, Alison R. , Phelps, Mitch

Mayo Clinic

Leukemia & Lymphoma | February 8, 2020 | Volume: 61 | Issue: 6 | Pages: 1484-1492

10.1080/10428194.2020.1719095 | PMID 32037935 Get It

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
Surinach, Andy , Corvino, Frank A., Torres, Aracelis Z. , Mamlouk, Khalid, Pulgar, Sonia, Valderrama, Adriana , Bekaii‐Saab, Tanios , Ahn, Daniel H. , Bekaii-Saab, Tanios S , Barzi, Afsaneh , Miksad, Rebecca Anne , Wang, Siqi

Mayo Clinic

Pancreas | February 6, 2020 | Volume: 49 | Issue: 2 | Pages: 193-200

10.1097/mpa.0000000000001479 | PMID 32011529 Get It

Objectives Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve survival in metastatic pancreatic cancer (mPC). This study describes real-world characteristics of patients treated with nal-IRI for mPC. Methods Patients 18 years or older diagnosed with stage IV mPC and treated with nal-IRI were selected retrospectively from a deidentified electronic health record database of more than 2 million US cancer patients. Demographics, clinical and dosing characteristics, and treatment outcomes were collected. Results Of 257 total patients, 145 (57%) received nal-IRI as first- or second-line therapy. Median nal-IRI treatment duration was 51 days, longer when nal-IRI was used as first/second versus as third-line therapy or later (62 vs 44.5 days). Seventy patients (27.2%) experienced dose modification. Median time to treatment discontinuation was 2.3 versus 1.6 months for first-/second- versus third-line therapy or later, respectively. Median overall survival from nal-IRI initiation was 5.6 versus 4.1 months for first-/second- versus third-line therapy or later, respectively. Prior irinotecan treatment, baseline serum albumin less than 40 g/L, and baseline neutrophil-to-lymphocyte ratio greater than 5 were associated with reduced overall survival. Conclusions This is the first large US study of real-world US mPC patients treated with nal-IRI. These results, comparable to the NAPOLI-1 trial, can help inform future studies and the efficacy of nal-IRI in mPC therapy.
Gender Differences in Faculty Rank and Leadership Positions Among Hematologists and Oncologists in the United States
Riaz, Irbaz Bin , Zahid, Umar, Durani, Urshila , Fatima, Kaneez , Sipra, Qurat-ul-Ain Riaz, Raina, Ammad, Farooq, Muhammad Zain, Chamberlain, Alanna M. , Marshall, Ariela L. , Khosa, Faisal , Marshall, Ariela , Chamberlain, Alanna M , Riaz, Irbaz B , Durani, Urshila , Siddiqi, Rabbia , Wang, Zhen , Go, Ronald S.

Mayo Clinic

JCO Oncology Practice | February 6, 2020 | Volume: 16 | Issue: 6 | Pages: e507-e516

10.1200/op.19.00255 | PMID 32048924 Get It

PURPOSE: Gender disparity persists in academic medicine. Female faculty are underrepresented in leadership positions and have lower research output. We studied gender differences in faculty rank and departmental leadership and contributing factors among academic hematologists and oncologists in the United States. METHODS: For clinical faculty at 146 hematology or oncology fellowship programs listed in the Fellowship and Residency Electronic Interactive Database, we collected data on demographics, academic rank, and research output using the Doximity and Scopus databases. We compared unadjusted characteristics of men and women by using 2-sided t tests and χ2 tests where appropriate. To predict probability of full professorship or leadership position among men versus women, we performed multivariable logistic regression analysis adjusted for clinical experience in years, number of publications, h-index, clinical trial investigator status, National Institutes of Health funding, and workplace ranking (top 20 v not). RESULTS: Two thousand one hundred sixty academic hematologists and oncologists were included. Women composed 21.9% (n = 142) of full professors, 35.7% (n = 169) of associate professors, and 45.4% (n = 415) of assistant professors. Thirty percent (n = 70) of departmental leaders were women. Female faculty, compared with male faculty, had a lower mean h-index (12.1 v 20.9, respectively; P < .001) and fewer years of professional experience since fellowship (10 v 16 years, respectively; P < .001). After adjusting for duration of clinical experience, academic productivity, and workplace ranking, the odds of obtaining professorship (odds ratio [OR], 1.05; 95% CI, 0.71 to 1.57; P = .85) or divisional leadership (OR, 0.57; 95% CI, 0.20 to 1.58; P = .28) for female physicians were not different compared with male physicians. CONCLUSION: Gender disparity exists in senior ranks of academic hematology and oncology; however, gender is not a significant predictor in achieving professorship or department leadership position.
Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
Sperduto, Paul W. , Li, Jing , Cagney, Daniel , Aizer, Ayal A. , Nesbit, Eric , Chan, Jason W., Breen, Will, Brown, Paul D. , Shi, Diana D. , Soliman, Hany , Sahgal, Arjun , Shanley, Ryan , Sperduto, William , Everett, Ashlyn S. , Boggs, Drexell H. , Masucci, Laura , Plichta, Kristin A. , Buatti, John M. , Jain, Supriya , Gaspar, Laurie E., Wu, Cheng–Chia , Wang, Tony J. C. , Bryant, John , Chuong, Michael D. , Chiang, Veronica , Nakano, Toshimichi , Shi, Diana , Buatti, John M , Wang, Tony J C , Mesko, Shane , Lin, Nancy U. , Kruser, Tim J. , Braunstein, Steve , Lee, Jessica , Kirkpatrick, John P. , Shih, Helen A. , Lou, Emil , Roberge, David , Remick, Jill S. , Bryant, John, Yu, James B. , Aoyama, Hidefumi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | February 6, 2020 | Volume: 22 | Issue: 9 | Pages: 1359-1367

10.1093/neuonc/noaa025 | PMID 32034917 Get It

Abstract Background Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). Methods A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. Results The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors—nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17–28 mo, P = 0.12; HER2, 15–19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27–18 mo, P = 0.02; HER2, 30–18 mo, P = 0.08). Conclusions Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. Key Points 1. Receptor discordance alters subtype in 32% of BCBM patients. 2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively. 3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
Capitellar Osteochondritis Dissecans Lesions of the Elbow: A Systematic Review of Osteochondral Graft Reconstruction Options
Logli, Anthony L. , Leland, Devin P. , Bernard, Christopher D. , Sánchez‐Sotelo, Joaquín , O’Driscoll, Shawn W. , Krych, Aaron J. , O'Driscoll, Shawn W., Sanchez-Sotelo, J. , Krych, Aaron J , Fitzsimmons, James S , Morrey, Mark E. , Wang, Zhen , Camp, Christopher L.

Mayo Clinic

Arthroscopy | February 5, 2020 | Volume: 36 | Issue: 6 | Pages: 1747-1764

10.1016/j.arthro.2020.01.037 | PMID 32035172 Get It

Purpose To systematically evaluate the outcomes and complications of osteochondral autograft transfer (OAT) and osteochondral allograft transplantation (OCA) for the surgical treatment of capitellar osteochondritis dissecans (OCD). Methods A literature search was conducted across 3 databases (PubMed, Cochrane, and CINAHL [Cumulative Index to Nursing and Allied Health Literature]) from database inception through December 2019 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Individual study quality was assessed using the Methodological Index for Non‐randomized Studies scale. Studies were published between 2005 and 2019. Results Eighteen studies consisting of 446 elbow OCD lesions treated with OAT surgery were included. There was a single OCA study eligible for inclusion. Patient ages ranged from 10 to 45 years. Of the OAT studies, 4 used autologous costal grafts whereas the remainder used autografts from the knee. Outcome measures were heterogeneously reported. A significant improvement in Timmerman‐Andrews scores from preoperatively to postoperatively was reported in 9 of 10 studies. Return‐to‐play rates to the preinjury level of competitive play ranged from 62% to 100% across 16 studies. Significant improvement in motion, most often extension, was noted in most studies. Reported complication, reoperation, and failure rates ranged from 0% to 11%, 0% to 26%, and 0% to 20%, respectively. When used, knee autografts resulted in low donor‐site morbidity (Lysholm scores, 70‐100). Conclusions OAT surgery for large, unstable OCD lesions of the capitellum reliably produced good outcomes, few complications, and a high rate of return to competitive play. Complications are relatively uncommon, and donor‐site morbidity is low. Less is known about the performance of OCA given the paucity of available literature. Level of Evidence Level IV, systematic review of Level II to IV studies.
Association of Home Noninvasive Positive Pressure Ventilation With Clinical Outcomes in Chronic Obstructive Pulmonary Disease
Wilson, Michael E. , Dobler, Claudia C. , Morrow, Allison S. , Beuschel, Bradley, Alsawas, Mouaz , Benkhadra, Raed, Seisa, Mohamed O. , Mittal, Aniket, Sánchez, Manuel Anguita , Daraz, Lubna , Holets, Steven R, Murad, M. Hassan , Seisa, Mohamed, Sanchez, Manuel, Holets, Steven, Murad, M Hassan , Alsawas, Mouaz , Wang, Zhen

Mayo Clinic

JAMA | February 5, 2020 | Volume: 323 | Issue: 5 | Pages: 455

10.1001/jama.2019.22343 | PMID 32016309 Get It

CYP2C9 and CYP2C19 : Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
Zhang, Lingxin , Sarangi, Vivekananda , Moon, Irene, Yu, Jia , Liu, Duan , Devarajan, Sandhya, Wang, Liewei , Weinshilboum, Richard M. , Reid, Joel M. , Weinshilboum, Richard, Liu, Duan , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Clinical and Translational Science | January 31, 2020 | Volume: 13 | Issue: 4 | Pages: 727-742

10.1111/cts.12758 | PMID 32004414 Get It

Single nucleotide variants in the open reading frames (ORFs) of pharmacogenes are important causes of interindividual variability in drug response. The functional characterization of variants of unknown significance within ORFs remains a major challenge for pharmacogenomics. Deep mutational scanning (DMS) is a high‐throughput technique that makes it possible to analyze the functional effect of hundreds of variants in a parallel and scalable fashion. We adapted a “landing pad” DMS system to study the function of missense variants in the ORFs of cytochrome P450 family 2 subfamily C member 9 ( CYP2C9 ) and cytochrome P450 family 2 subfamily C member 19 ( CYP2C19 ). We studied 230 observed missense variants in the CYP2C9 and CYP2C19 ORFs and found that 19 of 109 CYP2C9 and 36 of 121 CYP2C19 variants displayed less than ~ 25% of the wild‐type protein expression, a level that may have clinical relevance. Our results support DMS as an efficient method for the identification of damaging ORF variants that might have potential clinical pharmacogenomic application.